The EU-ADR Web Platform: delivering advanced pharmacovigilance tools
Article first published online: 4 DEC 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 22, Issue 5, pages 459–467, May 2013
How to Cite
Oliveira, J. L., Lopes, P., Nunes, T., Campos, D., Boyer, S., Ahlberg, E., van Mulligen, E. M., Kors, J. A., Singh, B., Furlong, L. I., Sanz, F., Bauer-Mehren, A., Carrascosa, M. C., Mestres, J., Avillach, P., Diallo, G., Díaz Acedo, C. and van der Lei, J. (2013), The EU-ADR Web Platform: delivering advanced pharmacovigilance tools. Pharmacoepidem. Drug Safe., 22: 459–467. doi: 10.1002/pds.3375
- Issue published online: 3 MAY 2013
- Article first published online: 4 DEC 2012
- Manuscript Accepted: 22 OCT 2012
- Manuscript Revised: 23 AUG 2012
- Manuscript Received: 20 JUN 2012
- adverse drug reactions;
- drug safety;
- in silico pharmacology
Pharmacovigilance methods have advanced greatly during the last decades, making post-market drug assessment an essential drug evaluation component. These methods mainly rely on the use of spontaneous reporting systems and health information databases to collect expertise from huge amounts of real-world reports. The EU-ADR Web Platform was built to further facilitate accessing, monitoring and exploring these data, enabling an in-depth analysis of adverse drug reactions risks.
The EU-ADR Web Platform exploits the wealth of data collected within a large-scale European initiative, the EU-ADR project. Millions of electronic health records, provided by national health agencies, are mined for specific drug events, which are correlated with literature, protein and pathway data, resulting in a rich drug–event dataset. Next, advanced distributed computing methods are tailored to coordinate the execution of data-mining and statistical analysis tasks. This permits obtaining a ranked drug–event list, removing spurious entries and highlighting relationships with high risk potential.
The EU-ADR Web Platform is an open workspace for the integrated analysis of pharmacovigilance datasets. Using this software, researchers can access a variety of tools provided by distinct partners in a single centralized environment. Besides performing standalone drug–event assessments, they can also control the pipeline for an improved batch analysis of custom datasets. Drug–event pairs can be substantiated and statistically analysed within the platform's innovative working environment.
A pioneering workspace that helps in explaining the biological path of adverse drug reactions was developed within the EU-ADR project consortium. This tool, targeted at the pharmacovigilance community, is available online at https://bioinformatics.ua.pt/euadr/. Copyright © 2012 John Wiley & Sons, Ltd.